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Expression quantitative trait locus analysis has emerged
as an important component of efforts to understand
how genetic polymorphisms influence disease risk and is
poised to make contributions to translational medicine.
Here we review how expression quantitative trait locus
analysis is aiding the identification of which gene(s)
within regions of association are causal for a disease or
phenotypic trait; the narrowing down of the cell types
or regulators involved in the etiology of disease; the
characterization of drivers and modifiers of cancer; and
our understanding of how different environments and
cellular contexts can modify gene expression. We also
introduce the concept of transcriptional risk scores as a
means of refining estimates of individual liability to
disease based on targeted profiling of the transcripts
that are regulated by polymorphisms jointly associated
with disease and gene expression.the prospects for incorporation of eQTL analysis into
translational personalized medicine.The importance of expression quantitative trait loci
The recognition that the majority of genotypes associ-
ated with diseases localize to regulatory regions [1, 2]
rather than to protein-coding regions has increased
interest in the effect of polymorphisms on gene expres-
sion. Although it may have started as something of a
high-profile academic curiosity 10 years ago [3, 4],
expression quantitative trait locus (eQTL) analysis has
become a key tool for the functional understanding of
the results of genome-wide association studies (GWASs)
[5]. Several thousand papers now refer to human eQTLs,
loci that associate with transcript abundance at genome-
wide significance levels. They help to explain risk for
diseases as diverse as autoimmune, cardiovascular and
metabolic diseases, as well as cancer, by focusing atten-
tion on causal genes within a defined interval. eQTLs* Correspondence: greg.gibson@biology.gatech.edu
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ence gene function as it relates to disease, particularly
where they alter experimentally or bioinformatically de-
fined sequence elements. In addition, they may have a role
in the prediction of the onset or course of a disease.
Recent trends in the field include meta-analysis of
ever-larger sample sizes to increase power, investigation
of more and more tissues, and incorporation of chroma-
tin measures to explore the mechanisms by which
eQTLs act. In addition, analytical algorithm develop-
ment has progressed as RNA-sequencing (RNA-seq) has
displaced microarrays as the primary means of measure-
ment of transcript abundance. We start this review by
explaining some of the key concepts and resources for
exploring eQTLs, but the major purpose is to highlight
the implications of eQTL analysis for genomic medicine.
To this end, we survey six areas where eQTL analyses
can provide insight into genetic regulation relevant to
health and disease, then conclude with a discussion ofDefinitions and key concepts
In humans, most eQTLs are mapped by GWASs using
genotyping arrays to measure the genotypes of up to
several million single nucleotide polymorphisms (SNPs),
and either microarrays or RNA-seq [6] to measure tran-
script abundance [7]. Statistical association between each
SNP and each transcript is computed, revealing places in
the genome where there is a linear change in average
transcript abundance with each copy of one of the alleles
(Fig. 1a). Imputation can be used to increase the search
space for possible causal variants, sometimes identifying
more statistically significant associations, but more
importantly expanding the list of possible causal variants
in the vicinity of the initial tagging SNP [8]. If the eQTL
polymorphism is located within the vicinity of the tran-
script, it is called a local eQTL, and the straightforward
interpretation is that it (or one or more other variants
in linkage disequilibrium with it) directly regulatesrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
































Fig. 1 Schematic of eQTLs. a eQTLs are defined as sites in the genome
where one of the alleles at a single nucleotide polymorphism (SNP) or
copy number variation (CNV) is associated with greater average
transcript abundance. Relative to disease risk, the allele that increases
expression (here A) may be associated with protection (as here) or
increased susceptibility (B). Note that there will always be some
number of individuals with the susceptibility or risk genotype whose
expression is well within the normal range or even tending in the
opposite direction. This consideration suggests that gene expression
may be a better indicator of risk than genotype alone, if it can be
measured in the right tissue under the right conditions. b Cis-eQTLs are
regulatory polymorphisms that influence transcription of a nearby
gene on the same chromosome. Heterozygotes are expected to show
allele-specific expression, since one of the alleles, in this case A, leads to
increased transcription relative to the other (G). In general it is assumed
that cis-eQTLs have differential affinities for transcription factors that
bind to promoter, enhancer or repressor elements located within
250 kb on either side of the transcription start site. Trans-eQTLs, on the
other hand, are polymorphisms at another locus, which increase or
decrease expression at both alleles to a similar extent
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Kruglyak in their recent review [5], if the effect is medi-
ated by influencing the binding of a transcription factor,
which in turn affects the activity of the RNA polymerase
complex on the same physical chromosome, formally
the local eQTL effect acts in cis [9]. Consequently, the
abundance of the transcript derived from that chromo-
some is altered, which gives rise also to a difference in
the overall expression level of the gene. By contrast,distal eQTLs act at a distance through an intermediary,
presumably affecting both chromosomes equivalently,
and hence are also called trans-eQTLs (Fig. 1b). For
practical purposes, whether or not an eQTL acts in cis
or in trans is usually defined simply by a distance
metric — perhaps the requirement that the polymorph-
ism lies within say 250 kb of the transcription start site of
the affected transcript, although local regulation can also
extend over 1 Mb [10] and some authors adopt this lon-
ger criterion. Conversely, some local eQTLs may influ-
ence transcription from both chromosomes to the same
degree, effectively acting in trans, so a more accurate def-
inition of cis and trans effects depends on the mechanism
of action.
The adoption of RNA-seq has led to the ability to
discriminate between variants that influence overall
transcript abundance, transcript isoform abundance,
allele-specific expression, and novel transcripts including
long noncoding RNAs (lncRNAs) [11, 12]. Although the
default assumption is that eQTLs regulate the initiation
of transcription, variants in the 3’ untranslated region
may also regulate steady-state abundance at the level of
transcript stability [13]. Others, termed protein abun-
dance QTLs, generally located toward the 5’ end of the
transcript, may regulate ribosome binding and hence
translation and protein levels without necessarily affect-
ing transcript abundance [14]. Alternative splicing can
lead to altered isoform abundance that may not be ap-
parent from microarray analyses that rely on probing of
common exons, or RNA-seq analysis pipelines that only
survey gene-level transcription. Results from a recent
large study of lymphoblast cell lines from the HapMap
collection [11] actually indicated that there is consider-
ably more variability at the levels of splicing and usage
of alternative transcription start or termination sites
than overall abundance. Since many of these differences
may be due to relatively rare variants that affect just a
few percent of individuals, it is difficult to quantify rela-
tive impacts. An important question requiring more
focused analysis is to what extent ethnic differences in
overall and isoform-specific transcription are due to
local eQTLs [15].
Whereas GWASs of disease or clinical phenotypes
generally require samples from thousands, if not tens of
thousands, of individuals to explain just a minority of
the genetic variance seen in a population [16], eQTL
analysis has the distinct advantage that significant results
can be obtained with as few as 100 samples. Obviously
power increases with sample size, and accordingly the
number of genes with identified local eQTLs rose from
around 5 % for 100 peripheral blood samples to ap-
proaching 50 % after meta-analysis of several thousand
samples [17]. This reflects increased resolution from var-
iants explaining at least 10 % of the transcript variance,
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sizes are large relative to clinical traits, presumably be-
cause the effect on binding of transcription or splicing
factors is direct. It is worth keeping in mind that the
relevant expression may be in a tissue other than the
one being profiled, so many associations will be missed
because the correct cell type has not been profiled.
Trans-eQTLs typically explain an order of magnitude
less variance than cis-eQTLs, and the vast majority of
trans effects remain unmapped, even though it is esti-
mated that between two thirds and three quarters of the
genetic component of gene expression in blood [18] and
adipose tissue [19] is due to trans-acting factors. Several
hundred trans-eQTLs have now been identified from
meta-analyses [17, 20]; most influence just a handful of
transcripts, and collectively they barely make a dent in
explaining the overall heritability of gene expression.
That is to say, if the average transcript has a heritability
of between 20 % and 50 %, and one quarter of this is
explained by one or two common local eQTLs, most of
the genetic variance remains unexplained.
Furthermore, a hallmark of transcriptomes is a high
degree of transcriptional covariance — rather than
10,000 independently transcribed genes per cell type,
modules of co-expression exist that influence hundreds
or even thousands of transcripts [21, 22]. In peripheral
blood, for example, seven major conserved variance
components explain well over half the variance of all
transcripts [23], reflecting coordinated regulation of
genes in the predominate cell types as well as the
strength of immune signaling activity, although we do
not yet know the genetic basis for this.
Resources
One of the most important aspects of eQTL analyses for
clinical studies is that the data and results are very often
made available in an easily accessible format. Although
the underlying gene expression data are almost always
deposited in one of the major public databases (Gene
Expression Omnibus (GEO) or ArrayExpress) [24, 25],









eQTLs expression quantitative trait loci, GTEx genotype tissue expression, GWAS geneQTL results. However, these can generally be accessed
either from the journal or individual investigators’ web-
sites, or by request. As the field transitions to whole-
genome sequencing in place of genotyping, in an effort
to identify rare-variant eQTLs, data access issues may
become more problematic, necessitating a reliance on
repositories that provide summary statistics [26].
Happily, there are several existing resources (highlighted
in Table 1) that facilitate browsing by any investigators
whether or not they have expertise in the underlying stat-
istical methods. The GeneVar database [27] at the Sanger
Institute, for example, presents results from 726 HapMap
lymphocyte cell lines and three different tissues
(lymphocyte cell line (LCL), adipose, and skin) from
856 healthy female twins enrolled in the MuTHER study,
in each case searchable either by transcript or eQTL
SNP. Manhattan plots visualize the significance of all of
the associations across a locus, while scatter plots
visualize the variance in transcript abundance for each
genotype at a single SNP. More recent HapMap Project
[28] results generated from whole-genome sequencing
and comprehensive RNA-seq are presented in a bespoke
genome browser at the Geuvadis resource [11]. For in-
vestigators interested in peripheral blood eQTLs, the
Blood eQTL browser [17] provides a meta-analysis of cis-
and trans-eQTL results from dozens of international
studies in table format, searchable by gene or SNP. Ap-
proximately half of all genes return no results, while a
handful return hundreds of results at extremely small
false discovery rate levels, reflecting high linkage disequi-
librium (but note that the database does not yet include
imputed SNPs). An emerging critical resource is the
genotype tissue expression (GTEx) Portal [29, 30], which
will allow users to query a database of eQTLs detected in
multiple tissues — initially 13 tissues from at least 60
postmortem donors but it is expected to include more
than 20 tissues in 900 donors by the end of 2015. The
NCBI is developing a searchable browser for this project
that allows users to select a tissue, apply filters, and
download reported eQTLs. Two other very useful re-
sources that integrate eQTLs with other types of genomicNature of data
oftware/genevar/ eQTL visualization tools
-das/ HapMap LCL eQTLs
wser/ Blood eQTL meta-analysis
Multi-tissue eQTL study
ts/gap/eqtl/index.cgi Searchable database of GTEx
eQTLs with genomic features
eQTLs with GWAS association
ome-wide association study, LCL lymphocyte cell line
Table 2 Some prominent recent eQTL publications
Reference Topic
Interaction effects
[108] Comprehensive two-locus interaction screen for epistatic
eQTL effects
[109] Debate surrounding epistatic interactions described in [108]
[110] Interaction effects influencing allele-specific gene expression
[111] QTLs influencing the variance of gene expression
[49] Estimation of architecture of variance from pedigree studies
Chromatin and epigenetics
[112] Genetic and epigenetic regulation of lncRNA expression
[113] Role of histone modification and transcription factor binding
on eQTL effects
[114] Identification of genetic variants influencing histone
modification
[115] Role of methylation QTLs in modifying eQTL effects
[116] Contributions of methylation and expression QTLs in
fibroblasts
Technical advances
[11] eQTL identification through RNA-seq plus whole-genome
sequencing
[117] Joint eQTL and protein expression analysis
[118] eQTLs in ten regions of the human brain
Disease studies
[93] eQTLs for the immune response to tuberculosis
[94] eQTLs in childhood malaria and parasitemia
[95] Changes in blood eQTL profile associated with myocardial
infarction
[119] eQTLs in COPD
[80] Cis-regulatory influences on gene expression in colorectal
cancer
Perturbation studies and response eQTLs
[84] Conditional dependence of eQTLs in monocytes
[85] Conditional dependence of eQTLs in lymphocytes
[86] Conditional dependence of eQTLs in dendritic cells
[15] Monocyte- and lymphocyte-specific eQTLs across ethnicities
COPD chronic obstructive pulmonary disease, eQTL expression quantitative
trait locus, lncRNA long noncoding RNA, RNA-seq RNA-sequencing
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laboratory resources hosted by the University of Chicago,
and the Pickrell laboratory GWAS browser hosted by the
New York Genome Center [31].
Once eQTLs are recognized to fall into extended
haplotype blocks in which hundreds of SNPs may be
responsible for the associations detected by GWASs, the
issue of fine-mapping the causal variant arises. For many
clinical purposes, this may not be important, but it is
also becoming clear that local eQTLs can operate over
hundreds of kilobases, affecting a gene or genes that are
not the most proximal to the causal SNP [9, 11]. In
addition, statistical arguments strongly support the infer-
ence that in many cases there may be multiple inde-
pendently acting SNPs responsible for the eQTL effect
at each locus [32–34]. Although there is no consistency
yet to the usage of the term eSNP (which is commonly
used interchangeably with eQTL), we suggest that fine-
mapped variants that are candidate causal mediators of
the eQTL observation should be called eSNPs.
Unfortunately, there is as yet no database for such
eSNPs, perhaps because there is only good functional
evidence for a small number of individual sites. In the
meantime, there are several resources that can help in-
vestigators narrow down the pool of candidate eSNPs
within an eQTL region. RegulomeDB [35], for example
(http://regulomedb.org/), ranks SNPs according to
whether there are functional data from a variety of
ENCODE assays. Type 1 SNPs have a known eQTL
association as well as evidence from DNase I hyper-
sensitive sites (DHSs), chromatin immunoprecipitation,
predicted transcription factor binding, or reporter gene
assays. HaploReg [36] serves a similar purpose. Several
related measures exist, including ones such as CADD
that integrate sequence conservation into the functional
inference [37, 38], and these have been shown to provide
useful prioritization of candidate variants for disease [39].
There is as yet little consistency to the use of these
scores. Another immediate need is high-throughput
functional assays to experimentally validate that individ-
ual sites do impact gene expression [40], and eventually
to establish whether and how multiple variants at a single
locus function together. Table 2 provides a list of some
prominent recent eQTL studies in four domains: inter-
action effects, integration with epigenetics, technical
advances, and eQTLs for response to perturbation.
Six uses for eQTL analysis in genome medicine
We turn now to the question of how eQTLs can be used
in the service of genomic medicine. As with other
measures derived from GWASs, the primary utility is in-
direct, namely improved understanding of disease mech-
anisms. Applications in personalized medicine, whether
diagnostic, predictive, or therapeutic, lie in the future,but we conclude the review with a discussion of the no-
tion of transcriptional risk scores.
Identifying which gene corresponds to a GWAS disease or
trait association
Undoubtedly the most direct application of eQTL ana-
lysis is in fine-mapping a GWAS association to a specific
gene within the interval. Given the linkage disequilib-
rium structure in the human genome, the resolution of
GWASs is typically to haplotype blocks that may
cover anywhere from 20 kb to upwards of 100 kb.
Cross-ethnicity comparisons may improve the resolution
Gibson et al. Genome Medicine  (2015) 7:60 Page 5 of 14[15, 41, 42], but even in the theoretical limit where just
a single SNP is shown to cause the peak association, it
cannot be concluded that the SNP acts on the nearest
gene. This is true of the situation both when the
GWAS SNP lies in a gene desert (where no known
transcripts have been identified) or lies in a high-gene-
density region. Since over three quarters of GWAS hits
appear not to be associated with potentially deleterious
protein-coding variants [1, 43], the vast majority are
likely to be regulatory. eQTL analysis provides an ef-
fective solution for quickly ascertaining which gene in a
region of association is most likely dysregulated in the
disease. Note that variants in the gene need not even
be in linkage disequilibrium with the eSNP.
A textbook example of this application is provided
by the hypercholesterolemia association identified at
chromosomal interval 1p13.3, where any one of seven
genes could plausibly be responsible for one of the lar-
gest known genetic effects on serum cholesterol levels
[44]. eQTL analysis in liver biopsies demonstrated that
the abundance of two transcripts, PSRC1 and SORT1,
tends to be highest in homozygotes for the minor allele,
with heterozygotes having an intermediate abundance.
Subsequently, substitution of the minor for the major
variant affecting a C/EBP transcription factor binding
site was shown to reduce expression from a luciferase
reporter gene, confirming the identity of rs12740374 as
the eSNP. Most importantly, both knockdown and in-
crease of Sort1, but not Psrc1, in mouse had the
predicted effects on elevating and reducing serum chol-
esterol levels, respectively [44]. Thus, eQTL profiling
reduced the set of candidate genes that needed to be
assayed to establish the identity of the causal gene —
and thereby to define a novel drug target, the Golgi
transmembrane receptor SORT1.
Most studies do not go to such experimental depths to
prove the identity of the causal gene that is regulated by
a GWAS SNP. The literature is full of inferential state-
ments based simply on the observation that a high per-
centage of disease associations localize to an eQTL. This
is a somewhat risky business, since the concordance of
two correlations — an SNP with gene expression and
with disease risk — does not establish causation and in-
stead could be due to pleiotropy. Nevertheless, there is
little doubt that peak associations are enriched for local
eQTL effects, and algorithms such as Regulatory Trait
Concordance [45] have been developed to provide statis-
tical support for the argument that the causal variant for
a particular eQTL is the same as a causal variant for a
GWAS hit. The aforementioned Geuvadis study [11]
also showed that the likelihood that a GWAS SNP is an
eQTL declines with its rank in a linkage disequilibrium
block: the peak association need not be the causal one,
but eQTL results are consistent with near-peak onesbeing the functional variant in many cases. Similarly, the
Coloc package in R weighs evidence that an SNP associ-
ates with two or more traits, which can include a disease
and transcript [46]. Further statistical method develop-
ment is expected to lead to substantial improvements in
fine-mapping causal regulatory variants, and may illu-
minate novel mechanisms that do not necessarily require
disruption of transcription factor binding [34].
Defining the cell types or regulators most likely involved
in the etiology of a disease
The pathophysiology of most common diseases is often
restricted to a limited number of tissue/cell types or
organ systems [47, 48]. Therefore, if the majority of the
genetic susceptibility for disease acts through gene regu-
lation, it is likely that tissue-specific eQTLs underlie
some disease risk. Owing mainly to accessibility, the ma-
jority of our knowledge about eQTLs comes from ex-
pression levels measured in either whole blood [49–51]
or isolated cellular components of blood [52, 53]. How-
ever, results from eQTL and whole-genome studies in
multiple tissues have demonstrated that the genetic
control of gene regulation often differs between tissues
[18, 54]. Overlap of eQTLs among tissues has been one
approach used to address the question of the degree of
common genetic control between tissues [19, 55, 56].
Most such studies have independently mapped eQTLs in
two or more tissues and contrasted the number of
eQTLs found in both tissues, arriving at estimates of the
overlap between a pair of tissues ranging from 12 to
80 %. These studies are important in that they identify
loci that have a common effect on transcripts between
tissues. However, there are clear limitations that restrict
the conclusions that can be drawn.
A principal limitation is the inability to detect eQTLs
that have small effect sizes, especially given the severe
multiple testing burden that is inherent in eQTL map-
ping. Alternative approaches that jointly weight the
probability of eQTLs across multiple tissues have been
demonstrated to increase power to detect multi-tissue
eQTLs [57]. Numerous other analytical issues influence
our ability to interpret comparative eQTL studies, in-
cluding technical issues related to data quality and ex-
perimental design, differences in the way that statistical
models are formulated, and variable sample sizes. Of
course, true heterogeneity of effects across tissues is also
certainly present.
An alternative way to address the question of cross-
tissue concordance is to ask what is the total amount of
genetic variance of transcript levels shared between tis-
sues? Such estimates, called cross-tissue heritability [18]
and genetic correlation analysis [49], use experimental
designs that include related individuals to estimate the
total amount of genetic variance that is shared between
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ability estimates in that they represent the sum of all
genetic effects, irrespective of their identification in an
eQTL analysis, and have suggested that, on average, the
total amount of genetic control shared between tissues is
low.
The tissue specificity of the genetic control of tran-
scripts leads to an interesting challenge when investigat-
ing the functional role of genome-wide association
(GWA) loci through eQTL interpretation in cases where
the pathophysiology of the disease stems from a different
set of tissues to the eQTL data [58]. A common limita-
tion in disease genomics studies is the difficulty of
obtaining pathologically relevant tissue on which to
measure expression. In such situations we would caution
against the over-interpretation of the mechanism by
which GWA causal loci influence disease susceptibility,
unless there is specific knowledge on shared genetic
control of the transcript levels between the relevant tis-
sues. To understand the mechanisms of disease suscepti-
bility and to develop preventative and targeted therapies,
we ultimately require knowledge of genetic control of
regulatory variation in many different tissues [3, 48, 55].
Projects such as GTEx [29] will provide an invaluable
tool for identifying eQTLs that are conserved across tis-
sues and cell types and will ultimately allow knowledge
gained from expression levels measured in more readily
available tissues to be better utilized.
Despite these limitations, various strategies are used to
infer, given a list of SNPs, which biological processes
they have in common and/or to generate an interaction
network that implicates a particular biochemical or
cellular process. These include text-mining (tools such
as GRAIL [59]), protein–protein interaction networks
(DAPPLE, STRING [60, 61]), and gene set enrichment
analysis [62]. One that is somewhat specific to eQTL
analysis is cell-type enrichment. The simplest strategy is
to ask in which cell type is the set of transcripts affected
by multiple different eQTLs most strongly expressed,
and whether there is a bias toward co-expression in a
particular cell type. Thus, for the approximately 100
known inflammatory bowel disease-associated loci, more
than half of which have eQTLs in blood, expression is
enriched in several immune cell types, notably T cells,
dendritic cells, and NK cells, but not B cells or neutro-
phils [63]. This does not prove that those cell types con-
tribute to the etiology (for example, elevated expression
in a low-abundance cell type could be pathological), but
it does seem intuitive that if multiple eSNPs act in the
same cell type, then that cell type is likely to contribute
to the disease or trait associated with the same SNPs.
Another example is the apparent enrichment of
schizophrenia-associated SNPs in the vicinity of genes
expressed in monocytes, and hence likely to impactderived macrophages and inflammation [64]. Actually,
this approach does not require that the SNPs are shown
to be eQTLs, it only requires that the transcript is
enriched in abundance in the cell type, but we envisage
that as projects such as GTEx expand the range of eQTL
tissues, actual eQTL signature enrichment will generate
more robust inferences.
Indirect incorporation of eQTLs into the enrichment
assessment was first reported by Maurano and col-
leagues [65], who drew inferences concerning cell type
specificity from DHS data. They started with the obser-
vation that regulatory variants are enriched in DHSs,
and asked whether the inclusion of increasing numbers
of low-significance GWAS associations resulted in
enrichment for DHSs in specific cell types that have
been extensively characterized as part of the ENCODE
project [66]. Positive results were observed for interleu-
kin (IL)-17-secreting T cells in samples from patients
with Crohn’s disease, confirming immunological experi-
ments, and for fetal cardiomyocytes in patients with car-
diac QT interval. Just as interestingly, DHSs were
relatively depleted from neuronal cell types with respect
to association with multiple sclerosis, strongly arguing
against a neuronal role in the pathology of this auto-
immune brain disease. In a parallel analysis, the authors
asked whether there was enrichment for predicted
transcription-factor-binding sites in the DHSs associated
with autoimmune diseases, malignancies, or neuro-
psychiatric disorders. They found 22 transcription fac-
tors with binding sites in at least eight DHSs that are
located in established GWAS loci, and generated an
immune regulatory network involving STAT1, STAT3,
NF-κB and PPAR-γ that is highly likely to mediate the
aberrant expression associated with disease [65]. Differ-
ent networks were implicated in the other two disease
categories.
Highlighting likely causal genes among differentially
expressed genes
A relatively underappreciated application of eQTL ana-
lysis is that it may facilitate scans of differentially
expressed genes for causal loci. As noted above, it is
common in transcriptome studies to observe that hun-
dreds of genes are co-expressed [22, 23]. Consequently,
when investigators contrast normal and diseased tissue,
they typically identify a large number of transcripts that
are either induced or suppressed in the cases compared
to controls [3, 67]. It is difficult to know which of these
genes contribute to the pathology of a disease, and
which are ‘going along for the ride’ owing to co-
expression. For example, comparison of peripheral blood
from healthy controls and Crohn’s disease patients re-
veals several hundred transcripts that are differentially
expressed [68], but only a fraction of these are associated
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GWAS loci being eQTLs). eQTL analysis suggests a
strategy for prioritizing the causal genes among the dif-
ferentially expressed ones, on the assumption that only
the co-expressed genes that also harbor a disease associ-
ation are causally involved.
We agree with the systems genomics perspective that
the intersection between differential expression, eQTLs,
and GWAS disease associations has the highest prob-
ability of highlighting genes most likely to contribute to
pathology [69, 70]. The advantage of eQTL analysis in
this context is that it does not require the large sample
sizes that disease GWASs require. Hence, lower-
significance SNPs can be scanned for eQTL effects, and
instead of asking whether the transcripts are enriched in
a cell type, it is possible to ask whether they are enriched
in the differentially expressed genes in patient samples.
To date, the vast majority of eQTL studies have been
performed on healthy controls, and only a handful of
studies have compared eQTLs in cases and controls.
The GTex project [30] is a very welcome development,
expanding the number of tissues available for eQTL ana-
lysis to include most sites of pathology (for example,
liver, kidney, ovary, testes, skin, various brain regions),
but it is unlikely to include large numbers of pa-
tients. However, tissue biopsies from patients are
often feasible and should be prioritized. Another pos-
sible approach will be the differentiation of induced
pluripotent stem cells from cases and controls [71],
although there is no guarantee that this will generate
expression profiles that mirror the pathological state
in patients.
Localizing potential drivers and modifiers of cancer
The Cancer Genome Atlas projects have been at the
forefront of integrative genomic approaches to disease
by generating datasets that combine whole-exome se-
quencing with RNA-seq from matched tumor–normal
tissue pairs [72–74]. Most of the emphasis in the field
has been on the detection of genes that are significantly
mutated in cancer, the so-called drivers that harbor dele-
terious somatic mutations more often than expected by
chance [75, 76]. In parallel, GWASs have revealed that
most cancers also have a common variant susceptibility
profile that includes regulatory variants [77]. Aberrant
methylation is also well recognized as a risk factor for
some classes of tumor, which indirectly implicates
altered transcription [78, 79]. Thus, while the search for
druggable targets has focused on aberrant protein se-
quences, there is increasing recognition that altered gene
and protein expression is an important component of
oncogenesis. Quite possibly, gene expression signatures
may emerge as predictors of therapeutic response to
drug or immune therapy.Recent studies of colorectal cancer have highlighted
two novel directions for eQTL analysis [80–82]. The first
is quantification of aberrant gene expression in tumor
relative to control tissue for the purpose of identifying
novel drivers. Just as an excess of somatic protein-
coding mutations in a subset of genes marks them as
likely cancer promoting genes, so too an excess of som-
atic regulatory mutations in theory should mark genes
whose loss or gain of activity contributes to tumor
growth. The analytical problem is that we do not as yet
have high-confidence tools for defining which somatic
mutations affect regulatory DNA, and the technical
problem is that it takes whole-genome, not just exome,
sequencing, to find novel mutations. To overcome these
issues, Ongen and colleagues [80] searched for tran-
scripts that displayed allelic dysregulation in colorectal
tumors relative to matched normal colon — that is,
genes for which the ratio of transcript abundance from
the two chromosomes had significantly changed.
Whether due to point mutations, loss of heterozygosity,
or even mutated trans-regulators, the existence of an
average of 200 events in each of 103 tumor pairs allowed
the authors to identify 71 potential regulatory drivers, 9
of which overlap with suspected drivers from protein-
coding mutations. Functional validation experiments will
be required to establish that the expression level of each
gene does drive or modulate cancer progression.
The second novel direction is the discovery of cryptic
eQTLs, which are regulatory polymorphisms whose
activity is condition-dependent [80, 83]. In the envir-
onment of the tumor, altered expression of critical
transcription or splicing factors renders regulatory
polymorphisms that are silent in normal tissue func-
tional. This possibility follows from the interpretation
that cis-eQTLs act through altered affinity of the two al-
leles for a regulatory protein. In the absence of that pro-
tein, there is no functional difference, but when the
nuclear environment changes the polymorphism now in-
fluences gene expression. This can occur in a positive or
negative fashion, and may affect genes that are or are not
actively transcribed in normal tissue. The research strat-
egy here is simply to compare eQTL profiles between
normal and tumor tissue and test for a significant inter-
action effect. Again, given the relatively large effect sizes
of eQTLs, it turns out that there is sufficient statistical
power to find condition-dependent effects even with
samples as small as 100 pairs. Furthermore, scans for
transcription-factor-binding sites found enrichment for
six proteins, IRX3, E2F4, NFIL3, TFAP2A, CUX1 and
LEF1, each of which was indeed altered in abundance in
the cancer biopsies [80]. Similar analyses of other cancer
types are eagerly awaited, as are efforts to assess whether
this type of analysis can have translational importance in
the context of personalized cancer treatment.
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Extending the concept of condition dependence, a series
of studies have begun to analyze how immune activation
affects gene expression regulation by explicitly perturb-
ing primary cells in culture and then contrasting eQTL
profiles with baseline [84–86]. A similar approach has
been applied in model organisms, giving rise to
“response eQTLs”, namely loci that are associated with
the response to perturbation [87]. The context is that
eQTL analysis of accessible tissues is intrinsically limited
if the effects that are clinically relevant are highly
condition-specific. Immunologists, for example, have
emphasized that the properties of myeloid and lymphoid
cells are very different between circulating peripheral
blood and sites of infection or inflammation, that cellu-
lar age is relevant to function, and that stimulation of
immune cells elicits transcriptional responses. To this
end, eQTL profiling of distinct cell types such as mono-
cytes, T cells, and dendritic cells does identify eQTLs
that are cell-type specific and not recovered in periph-
eral blood mixtures (and lymphoblast cell lines appear
to be quite different again). Cell-type-specific eQTLs
might also be recovered by including measured cell-type
abundance as a covariate in the regression model used
to identify associations in tissues that are a mixture of
cells [88], such as blood. It should be emphasized that
the majority of eQTLs observed in leukocytes are con-
sistent across cell types [53], but it is possible that the
10–20 % that have opposite effects in, or are only
observed in, one cell type are the most critical for indi-
vidual pathology.
The ImmGen consortium recently published two
papers examining the impact of ex vivo activation on
dendritic cells and T lymphocytes [85, 86], and Fairfax
and colleagues [84] published a similarly impressive
study of monocytes. The three critical messages of these
studies are: (1) that activation state does alter eQTL pro-
files quite substantially, with half of all naïve-state
eQTLs disappearing upon stimulation and at least as
many only observed in stimulated cells; (2) there is a
temporal dynamic to the response profiles as cells move
through their regulatory state switch; and (3) several key
shifts involve key immune mediators that have been re-
peatedly identified in GWASs for inflammatory and
autoimmune diseases. For example, Lee and colleagues
[86] differentiated peripheral blood monocytes into
dendritic cells from 534 healthy donors, and then stimu-
lated them with lipopolysaccharide, influenza virus, or
interferon-β. They detected 121 response eQTLs from a
targeted analysis of 415 immunity-related genes, 57 of
which were common to all three treatments and 38 im-
plicated in inflammatory or autoimmune disease. One of
these, affecting the expression of interferon response fac-
tor 7 (IRF7) in cis, was in turn a trans-eQTL for sevenother genes after influenza virus stimulation. Targeted
replacement of another SNP that binds the interferon-
response transcription factor STAT2 by CRISPR/Cas9
abrogated the stimulus response of the eQTL SLFN5.
Clearly the clever combination of eQTL analysis with
experimental perturbation has great potential to illu-
minate the genetic basis of individual immunological
responses.
These results raise the question, taken up again in the
final section of this review, of whether eQTL profiling
may be useful in translational medicine. An underappre-
ciated aspect of genetic prediction is that no matter the
specificity and sensitivity of genotypic risk scores (GRSs),
predictive utility will always be constrained by the herit-
ability and prevalence of the disease. If the heritability is
less than 50 %, which is the case for most diseases, the
best genetics can do is classify individuals into risk cat-
egories. If the disease is rare, often in the vicinity of 1 %
prevalence there will always be a high ratio of unaffected
to affected individuals who have GRSs in the upper
quartiles or deciles [89, 90]. Consequently, there is con-
siderable interest in using gene expression as a bio-
marker for disease prediction, and/or to help classify
disease subtypes among affected individuals. The expres-
sion levels of genes that are regulated by eQTLs that are
also associated with disease would seem a priori to be
strong candidate biomarkers. The context-dependence
of eQTL effects suggests, however, that the expression
profiling will need to be performed either in situ, at the
site of pathology, or ex vivo under conditions that mimic
pathogenesis.
Exploration of genotype-by-environment interactions
It follows, to the extent that environment modifies dis-
ease risk, that gene expression should also be evaluated
in the context of the environment within which individ-
uals live. Given the global epidemiological transition to-
wards diseases that are prevalent in the Western world,
arguably the most relevant environmental parameter is
lifestyle. To this end, Idaghdour and colleagues surveyed
gene expression in peripheral blood from desert nomads,
urban slum dwellers, and rural villagers in southern
Morocco [91]; they observed pervasive differentiation
among these populations independent of ethnicity,
involving at least a third of the transcriptome. Similar
results were observed on a smaller scale for Indian vil-
lagers relative to residents of Suva in Fiji [92]. However,
eQTL analysis of the Moroccan sample was conspicuous
for the complete absence of genotype-by-environment
interactions (G × E) involving common regulatory poly-
morphisms: at each one of approximately 400 eQTLs,
the sign and magnitude of effect was the same for rural
villagers and city residents despite significant main effects
of population [91]. This result implies that cis-eQTL effects
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paper, it nevertheless suggests a mechanism for G × E at
the level of high-order phenotypes, since individuals be-
yond thresholds of high or low expression will tend to be
those with the combination of the relevant homozygous
genotype living in the environment in which expression
tends to be greater or lesser in general.
Another type of environmental factor that could mod-
ify eQTL effects is disease status, as described for cancer
above. Active tuberculosis, for example, impacts the ex-
pression of thousands of genes, and induces condition-
dependent eQTL effects for key modulators of immune
signaling [93]. High parasitemia also pervasively alters
peripheral blood gene expression, likely via signaling be-
tween infected red blood cells and lymphocytes, and,
correspondingly, eQTLs are affected [94]. A third ex-
ample is atherosclerosis, as individuals at high risk of
myocardial infarction have dozens of modulated eQTL
effects [95], again in peripheral blood — although to
date these have not been linked to variants that associate
with myocardial infarction. More studies contrasting
healthy and diseased individuals, in a diversity of tissues,
are needed before we can draw general conclusions
regarding how disease modifies eQTL profiles. One
interpretation is that the changes are merely in re-
sponse to pathology, but the more compelling possi-
bility is that possession of specific eQTL profiles
results in altered transcriptome states that are them-
selves pathological.
A third important cellular environmental factor is that
afforded by genetic population structure, namely differ-
ences in allele frequencies among populations. Several of
the first eQTL studies established that in LCLs at least
15 % of transcripts are differentially expressed among
the three major population groups represented in the
HapMap samples (Yoruban Africans, Caucasians, and
Han or Japanese East Asians), and, correspondingly,
population-specific local eQTLs were identified [96, 97].
Similar results are found using peripheral blood, driven
either by differential abundance of cell types such as
neutrophils and T helper 17 cells, or by differential ef-
fects of eQTLs within cells [98]. Owing to allele fre-
quency differences among populations, statistical power
to detect eQTLs can vary, so the identification of
population-specific effect sizes requires a significant
interaction effect. The aforementioned ImmGen Consor-
tium has demonstrated that at least 30 % of eQTLs in
lymphocytes fail to replicate across all three population
groups, but the proportion of local eQTLs that truly
have different effect sizes is likely to be somewhat less
[15]. Of particular clinical relevance will be establishing
to what degree effects differ upon stimulation or in dis-
eased tissues, and, subsequently, whether any differences
have population-biased therapeutic implications.eQTLs in translational medicine
In this review, we have discussed various ways in which
eQTL analysis is impacting genome medicine from the
perspective of understanding mechanisms of disease. We
conclude with some thoughts on whether eQTLs may
also be of more translational importance. As with findings
derived from GWASs and whole-exome sequencing, there
are at least three opportunities for translation: precision
medicine, prediction, and nosology.
Precision medicine refers to efforts to identify the
proximate genetic cause of a disease or condition in an
individual patient [99, 100]. It has quickly gained atten-
tion through the rapid introduction of next-generation
sequencing approaches in the domains of cancer and
pediatric congenital abnormalities, where the objective is
to identify one or a few rare mutations that may explain
the pathology. Even though it is doubtful that most vari-
ants are fully penetrant and thus sufficient to explain
causality completely, the overwhelming evidence is that
in more than a quarter of cases, whole-exome sequencing
can identify necessary deleterious variants [101, 102].
Many believe that rare regulatory ‘causal’ variants will also
be identified once the switch to whole-genome sequencing
is made and algorithmic detection of regulatory defects
improves. Such variants will by definition be rare local
eQTLs. Their definitive identification will be aided by
high-throughput methods for establishing a functional
impact on transcript abundance.
Genetic prediction refers to efforts to establish relative
risks for individuals based on the sum of their genotypic
risks [103]. Most often it assumes a GRS, but here we
introduce the concept of a transcriptional risk score
(TRS). This is the sum of standardized gene expression
measures for transcripts influenced by eQTLs for a dis-
ease, measured where possible in the relevant tissue. It is
not the same as a predictor based on quantitative trait
transcripts [104, 105], which are simply transcripts
found to be associated with a trait. Rather, it is asking
whether a joint measure of transcript abundance due to
GWAS associations is a better predictor of the trait or
disease than an allelic sum. For inflammatory or auto-
immune disorders, for example, GWASs have identified
upwards of 100 risk loci, the majority of which are
eQTLs [63]. We can polarize gene expression relative to
risk by assessing whether the high-risk genotype is asso-
ciated with increased or decreased transcript abundance,
and then sum the polarized z-scores to generate a TRS,
which will be correlated with the GRS.
To illustrate this concept, we performed a simulation
study assuming that disease incidence is affected by the
expression of 100 genes, each regulated by a single
eQTL that explains 25 % of its variance yet is associated
with a less than 1.2-fold increase in disease susceptibil-
ity. Collectively these eQTL explain one half of the risk.
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additive. This is indeed the case, as the area under the
receiver operating curve for the TRS is significantly
greater than the corresponding GRS (Fig. 2c shows a
typical iteration). There are many different classes of
model that can explain the relationship between gene
expression and disease, leading to different types of TRS,
including weighting of the eQTL effect size, only consid-
ering extreme expression values, and incorporating the
structure of the affected pathway into the analysis.
Unfortunately, we were not able to identify sufficiently
large eQTL disease studies to test the proposition that
TRSs have greater predictive utility than GRSs.
Finally, eQTLs have considerable potential for nos-
ology. Whereas GWASs typically make no attempt to
sub-classify individuals with respect to genotypic risk,
there are signs that once large numbers of loci have been
identified it may be fruitful to consider the nature of the
risk variants that each individual possesses in order to
better understand individualized sources of risk. For ex-
ample, type 2 diabetes risk alleles can be divided into
those that more strongly affect insulin production
(homeostatic model assessment (HOMA)-B) or insulin
resistance (HOMA-IR), and it follows that individuals
with SNP profiles biased in either direction may have
different subtypes of diabetes [106]. Similarly, rheuma-
toid arthritis variants affect genes that can be placed in
pathways that respond differently to various drugs, and
it is plausible that treatment might be targeted in an in-
dividualized manner on the basis of enrichment of vari-
ants linked to specific drugs [107]. This notion is readily
generalized to the supposition that individuals who share
combinations of eQTLs may exhibit particular sympto-
mology and/or respond to specific treatments. Ideally, it
would not be necessary to actually measure gene expres-
sion in the patient if eQTLs defined in an independent
disease cohort prove to be strongly predictive enough to
classify individuals by genotype alone.
Conclusion
These considerations lead us toward a model for person-
alized medicine in which genotype and transcript abun-
dance are utilized in an integrative manner. In some
cases, a single eQTL may be sufficient to highlight a crit-
ical risk factor or pharmacogenetic target, in others it
may be a cumulative eQTL risk score, and of course in
others gene expression may prove to be either unneces-
sary or uninformative. The field is currently benefiting
from the incorporation of ENCODE data for the pur-
poses of refining eQTLs to causal eSNPs, and from the
development of tools for meta-analysis that are greatly
increasing resolution. Open source databases are ensur-
ing that the results of studies are widely accessible, and
we expect that pooling of resources will also facilitatemega-analyses that provide opportunities for deeper stat-
istical inference. Once these approaches are extended to
diverse tissues through projects such as GTEx, and
eventually to comparisons of diseased and normal tis-
sues, eQTLs are set to become a core component of per-
sonalized medicine.
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